A Massachusetts-based biotech firm that’s creating a blood test for autism just got a major boost, from Google. SynapDx announced a $15.4 million funding round led by Google Ventures--an investment that could create a world-changing diagnostic tool: a blood test for children that accurately diagnoses autism spectrum disorders.
SynapDx’s autism blood test is currently in the early clinical trial phase. The company is seeking participants for its clinical trials at 20 sites nationwide, with the end goal of accurate autism diagnoses in children as young as 19 months old. The earlier children can be diagnosed, the more likely it is that interventions will work.